ERBB2 and breast carcinoma: This comprehensive study reports the successful synthesis, characterization, biological evaluation, and computational analysis of a new class of quinolin-2(1H)-one derivatives designed to function as dual inhibitors of EGFR and HER-2; two critical tyrosine kinases implicated in various cancers, including breast carcinoma.